Genentech, Inc. (NYSE:DNA), GlycArt, a company wholly-owned by Roche, and Roche (SWX:ROG) have entered into a collaboration agreement, including a license from GlycArt to Genentech, for the joint development and commercialization of GlycArt’s GA101 molecule.